Treatment-related mortality with vascular endothelial growth factor receptor tyrosine kinase inhibitor therapy in patients with advanced solid tumors: A meta-analysis

Cancer Treatment Reviews

Volumn 38, Issue 7, 2012, Pages 919-925

  Sivendran, Shanthi ^a   Liu, Ziyue ^b   Portas Jr , Louis J ^c   Yu, Menggang ^b   Hahn, Noah ^d   Sonpavde, Guru ^e   Oh, William K ^a   Galsky, Matthew D ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Cancer; Fatal adverse events; Meta analysis; Mortality; Pazopanib; Renal cell cancer; Sorafenib; Sunitinib; Vandetanib; Vascular endothelial growth factor

Indexed keywords

CAPECITABINE; CARBOPLATIN; PACLITAXEL; PAZOPANIB; SORAFENIB; SUNITINIB; VANDETANIB;

ADVANCED CANCER; BREAST CANCER; CANCER PATIENT; CANCER THERAPY; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CLINICAL TRIAL (TOPIC); CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DRUG FATALITY; FEMALE; HEART INFARCTION; HUMAN; INCIDENCE; INTESTINE PERFORATION; KIDNEY CARCINOMA; KIDNEY METASTASIS; LIVER CELL CARCINOMA; LIVER FAILURE; LUNG EMBOLISM; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MEDLINE; META ANALYSIS; PANCREATIC NEUROENDOCRINE TUMOR; PNEUMONIA; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY FAILURE; REVIEW; RISK FACTOR; SEPSIS; SOLID TUMOR;

CARCINOMA, RENAL CELL; HUMANS; KIDNEY NEOPLASMS; NEOPLASMS; PROTEIN KINASE INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR;

EID: 84865439183     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2012.05.001     Document Type: Review

References (28)

1. Hicklin D.J., Ellis L.M. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005 Feb 10, 23(5):1011-1027.
2. Cheng A.L., Kang Y.K., Chen Z., Tsao C.J., Qin S., Kim J.S., et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009 Jan, 10(1):25-34.
3. Demetri G.D., van Oosterom A.T., Garrett C.R., Blackstein M.E., Shah M.H., Verweij J., et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006 Oct 14, 368(9544):1329-1338.
4. Escudier B., Eisen T., Stadler W.M., Szczylik C., Oudard S., Siebels M., et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007 Jan 11, 356(2):125-134.
5. Escudier B., Szczylik C., Hutson T.E., Demkow T., Staehler M., Rolland F., et al. Randomized phase II trial of first-line treatment with sorafenib versus interferon alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol 2009 Mar 10, 27(8):1280-1289.
6. Llovet J.M., Ricci S., Mazzaferro V., Hilgard P., Gane E., Blanc J.F., et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008 Jul 24, 359(4):378-390.
7. Motzer R.J., Hutson T.E., Tomczak P., Michaelson M.D., Bukowski R.M., Oudard S., et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009 Aug 1, 27(22):3584-3590.
8. Raymond E., Dahan L., Raoul J.L., Bang Y.J., Borbath I., Lombard-Bohas C., et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011 Feb 10, 364(6):501-513.
9. Choueiri T.K., Schutz F.A., Je Y., Rosenberg J.E., Bellmunt J. Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. J Clin Oncol 2010 May 1, 28(13):2280-2285.
10. Ranpura V., Hapani S., Wu S. Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis. JAMA 2011 Feb 2, 305(5):487-494.
11. Moher D., Liberati A., Tetzlaff J., Altman D.G. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009, 339:b2535.
12. Jadad A.R., Moore R.A., Carroll D., Jenkinson C., Reynolds D.J., Gavaghan D.J., et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials 1996 Feb, 17(1):1-12.
13. DerSimonian R., Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986 Sep, 7(3):177-188.
14. Arnold A.M., Seymour L., Smylie M., Ding K., Ung Y., Findlay B., et al. Phase II study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy: National Cancer Institute of Canada Clinical Trials Group Study BR.20. J Clin Oncol 2007 Sep 20, 25(27):4278-4284.
15. Barrios C.H., Liu M.C., Lee S.C., Vanlemmens L., Ferrero J.M., Tabei T., et al. Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer. Breast Cancer Res Treat 2010 May, 121(1):121-131.
16. Heymach J.V., Paz-Ares L., De Braud F., Sebastian M., Stewart D.J., Eberhardt W.E., et al. Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol 2008 Nov 20, 26(33):5407-5415.
17. Motzer R.J., Hutson T.E., Tomczak P., Michaelson M.D., Bukowski R.M., Rixe O., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007 Jan 11, 356(2):115-124.
18. Natale R.B., Bodkin D., Govindan R., Sleckman B.G., Rizvi N.A., Capo A., et al. Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized phase ii study. J Clin Oncol 2009 May 20, 27(15):2523-2529.
19. Natale R.B., Thongprasert S., Greco F.A., Thomas M., Tsai C.M., Sunpaweravong P., et al. Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol 2011 Mar 10, 29(8):1059-1066.
20. Sternberg C.N., Davis I.D., Mardiak J., Szczylik C., Lee E., Wagstaff J., et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010 Feb 20, 28(6):1061-1068.
21. Wildiers H., Fontaine C., Vuylsteke P., Martens M., Canon J.L., Wynendaele W., et al. Multicenter phase II randomized trial evaluating antiangiogenic therapy with sunitinib as consolidation after objective response to taxane chemotherapy in women with HER2-negative metastatic breast cancer. Breast Cancer Res Treat 2010 Sep, 123(2):463-469.
22. Moher D., Cook D.J., Eastwood S., Olkin I., Rennie D., Stroup D.F. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of reporting of meta-analyses. Lancet 1999 Nov 27, 354(9193):1896-1900.
23. Juni P., Nartey L., Reichenbach S., Sterchi R., Dieppe P.A., Egger M. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet 2004 Dec 4-10, 364(9450):2021-2029.
24. Singh S., Loke Y.K., Furberg C.D. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 2007 Sep 12, 298(10):1189-1195.
25. Bennett C.L., Silver S.M., Djulbegovic B., Samaras A.T., Blau C.A., Gleason K.J., et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 2008 Feb 27, 299(8):914-924.
26. Chou R., Helfand M. Challenges in systematic reviews that assess treatment harms. Ann Intern Med 2005 Jun 21, 142(12 Pt 2):1090-1099.
27. Richards C.J., Je Y., Schutz F.A., Heng D.Y., Dallabrida S.M., Moslehi J.J., et al. Incidence and risk of congestive heart failure in patients with renal and nonrenal cell carcinoma treated with sunitinib. J Clin Oncol 2011 Sep 1, 29(25):3450-3456.
28. Schutz F.A., Je Y., Richards C.J., Choueiri T.K. Meta-analysis of randomized controlled trials for the incidence and risk of treatment-related mortality in patients with cancer treated with vascular endothelial growth factor tyrosine kinase inhibitors. J Clin Oncol 2012 Mar 10, 30(8):871-877.